- Conditions
- Systemic Sclerosis
- Interventions
- SAR156597, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 4
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Cleveland, Ohio + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Diet Habit, Rheumatologic Disease, Autoimmune Diseases, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Dermatomyositis/polymyositis, Sjogren's Syndrome, Systemic Lupus Erythematous, Scleroderma, Fibromyalgia
- Interventions
- Not listed
- Lead sponsor
- University of Central Florida
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Morphea, Plaque Form
- Interventions
- Sarilumab
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Raynaud Disease, Raynaud Disease Secondary to Scleroderma, Raynaud Secondary to Other Autoimmune Disease
- Interventions
- topical organogel with nitroglycerin
- Drug
- Lead sponsor
- MediQuest Therapeutics
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Seattle, Washington
- Conditions
- Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma, Raynaud's Disease Secondary to Autoimmune Disease
- Interventions
- MQX-503
- Drug
- Lead sponsor
- MediQuest Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 15 participants
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Renton, Washington
- Conditions
- Raynaud's Disease, Raynaud Phenomena, Raynauds
- Interventions
- Oral treprostinil (UT-15C) sustained release tablets
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Autoimmune Diseases, Pregnancy Related, Systemic Lupus Erythematosus, Cutaneous Lupus, Rheumatoid Arthritis, Sjogren's Syndrome, Scleroderma
- Interventions
- Not listed
- Lead sponsor
- Duke University
- Other
- Eligibility
- Female only
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Morphea, Localized Scleroderma
- Interventions
- topical calcipotriene 0.005% ointment
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Systemic Lupus Erythematosus, Systemic Sclerosis
- Interventions
- Reduced Intensity Allogeneic Transplant, Fludarabine, Busulfan, Campath
- Procedure · Drug
- Lead sponsor
- New York Medical College
- Other
- Eligibility
- 7 Years to 50 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- SCAD, Addison Disease, Ankylosing Spondylitis, Antiphospholipid Antibody Syndrome, Celiac Disease, Crohn Disease, Dermatomyositis, Polymyositis, Guillain-Barre Syndrome, Hepatitis, Autoimmune, Graves Disease, Hashimoto Thyroiditis, Multiple Sclerosis, Myasthenia Gravis, Pernicious Anemia, Polymyalgia Rheumatica, Primary Biliary Cirrhosis, Psoriasis, Rheumatoid Arthritis, Systemic Sclerosis, Sjögren Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Type 1 Diabetes Mellitus, Ulcerative Colitis, Uveitis, Vasculitis, Vitiligo, Raynaud
- Interventions
- Not listed
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 110 Years
- Enrollment
- 114 participants
- Timeline
- 1995 – 2020
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Systemic Sclerosis, Scleroderma
- Interventions
- Ambrisentan
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 19 Years to 90 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Rheumatic Diseases, Adult Onset Still Disease, Ankylosing Spondylitis, Psoriatic Arthritis, Reactive Arthritis, Antiphospholipid Syndrome, Systemic Lupus Erythematosus, Behcet Disease, Dermatomyositis, Polymyositis, Giant Cell Arteritis, Lyme Disease, Mixed Connective Tissue Disease, Polymyalgia Rheumatica, Rheumatoid Arthritis, Sarcoidosis, Systemic Sclerosis, Scleroderma, Sjogren's Syndrome, Undifferentiated Connective Tissue Diseases
- Interventions
- Not listed
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 5,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2030
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, Dermatomyositis
- Interventions
- VIB7734, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 19
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Los Angeles, California + 16 more
- Conditions
- Scleroderma, Localized, Morphea, Scleroderma, Circumscribed
- Interventions
- UVA-1 Phototherapy, Placebo
- Procedure
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 6 Years to 95 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Systemic Sclerosis (SSc)
- Interventions
- Efgartigimod PH20 SC, Placebo PH20 SC
- Combination Product · Other
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Los Angeles, California • Plantation, Florida + 6 more
- Conditions
- Systemic Sclerosis
- Interventions
- Belimumab, Rituximab, Placebo Subcutaneous Injection, Placebo Infusion, MMF
- Drug · Other
- Lead sponsor
- Hospital for Special Surgery, New York
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Scleroderma, Diffuse, Scleroderma, Systemic, Scleroderma, Limited, Sclerosis, Progressive Systemic, Skin Diseases, Connective Tissue Diseases, Pathologic Processes, Autoimmune Diseases
- Interventions
- Oral Ifetroban, Oral Placebo
- Drug
- Lead sponsor
- Cumberland Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 10
- States / cities
- Tucson, Arizona • Los Angeles, California • Weston, Florida + 7 more
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Scleroderma
- Interventions
- Mindfulness Based Stress Reduction (MBSR), Control
- Behavioral · Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Systemic Sclerosis
- Interventions
- treprostinil diethanolamine
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 19 more
- Conditions
- Autoimmune Diseases, Connective Tissue Diseases, Scleroderma, Circumscribed, Scleroderma, Systemic
- Interventions
- Not listed
- Lead sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- NIH
- Eligibility
- Not listed
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1992 – 2000
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Scleroderma, Systemic, Sclerosis, Autoimmune Disease
- Interventions
- mHSCT, cyclophosphamide
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2016
- U.S. locations
- 15
- States / cities
- Duarte, California • Los Angeles, California • Lexington, Kentucky + 10 more
- Conditions
- Sclerosis, Systemic
- Interventions
- Placebo, tocilizumab [RoActemra/Actemra]
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 21
- States / cities
- Los Angeles, California • San Diego, California • Stanford, California + 18 more
- Conditions
- Raynaud Phenomenon Secondary to Systemic Sclerosis
- Interventions
- Placebo IV infusion, Iloprost Injection, for intravenous use
- Drug
- Lead sponsor
- Civi Biopharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 16
- States / cities
- Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 12 more
- Conditions
- Systemic Sclerosis
- Interventions
- BMS-986353, Fludarabine, Cyclophosphamide, Tocilizumab, Rituximab, Nintedanib
- Drug
- Lead sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 17
- States / cities
- Scottsdale, Arizona • Aurora, Colorado • Denver, Colorado + 14 more